aDBS reflects that commitment, bringing a new expectation in Parkinson’s treatment.” The US FDA approval also includes the Medtronic BrainSense Electrode Identifier, which helps reduce patient time ...

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous ...

GALWAY, Ireland - Medtronic plc (NYSE ... streamlines the initial programming of DBS devices, reportedly performing 85% faster than traditional methods. This tool aids clinicians in accurately ...

The FDA approval also includes the Medtronic BrainSense Electrode Identifier, which helps reduce patient time spent in clinic to program their DBS settings.

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease.The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...

The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. By using EI, clinicians ...

The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice. The FDA approval also includes the ...